Literature DB >> 16869764

Deciphering cancer complexities in genetically engineered mice.

K Simin1, R Hill, Y Song, Q Zhang, R Bash, R D Cardiff, C Yin, A Xiao, K McCarthy, T van Dyke.   

Abstract

Because the pRb pathway is disrupted in most solid human cancers, we have generated genetically engineered mouse cancer models by inactivating pRb function in several cell types, including astrocytes and mammary, prostate, ovarian, and brain choroid plexus epithelia. In every case, proliferation and apoptosis are acutely induced, predisposing to malignancy. Cell type dictates the pathways involved in tumor progression. In the astrocytoma model, we developed strategies to induce events in the adult brain, either throughout the tissue or focally. Both K-Ras activation and Pten inactivation play significant roles in progression. In the prostate model, adenocarcinoma progression depends on Pten inactivation. However, nonautonomous induction of p53 in the mesenchyme leads to evolution of both compartments, with p53 loss occurring in the mesenchyme. Thus, studies in these models continue to identify key tumorigenesis mechanisms. Furthermore, we are hopeful that the models will provide useful preclinical systems for diagnostic and therapeutic development.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16869764     DOI: 10.1101/sqb.2005.70.038

Source DB:  PubMed          Journal:  Cold Spring Harb Symp Quant Biol        ISSN: 0091-7451


  6 in total

1.  Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.

Authors:  Ludmila Szabova; Chaoying Yin; Sujata Bupp; Theresa M Guerin; Jerome J Schlomer; Deborah B Householder; Maureen L Baran; Ming Yi; Yurong Song; Wenping Sun; Jonathan E McDunn; Philip L Martin; Terry Van Dyke; Simone Difilippantonio
Journal:  Cancer Res       Date:  2012-05-22       Impact factor: 12.701

Review 2.  GI GEMs: genetically engineered mouse models of gastrointestinal disease.

Authors:  Thomas Doetschman
Journal:  Gastroenterology       Date:  2010-12-15       Impact factor: 22.682

3.  Loss of cryptochrome reduces cancer risk in p53 mutant mice.

Authors:  Nuri Ozturk; Jin Hyup Lee; Shobhan Gaddameedhi; Aziz Sancar
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

4.  The current state of preclinical prostate cancer animal models.

Authors:  Kenneth J Pienta; Cory Abate-Shen; David B Agus; Ricardo M Attar; Leland W K Chung; Norman M Greenberg; William C Hahn; John T Isaacs; Nora M Navone; Donna M Peehl; Jonathon W Simons; David B Solit; Howard R Soule; Terry A VanDyke; Michael J Weber; Lily Wu; Robert L Vessella
Journal:  Prostate       Date:  2008-05-01       Impact factor: 4.104

5.  Carcinoma initiation via RB tumor suppressor inactivation: a versatile approach to epithelial subtype-dependent cancer initiation in diverse tissues.

Authors:  Yurong Song; Debra Gilbert; T Norene O'Sullivan; Chunyu Yang; Wenqi Pan; Alisan Fathalizadeh; Lucy Lu; Diana C Haines; Philip L Martin; Terry Van Dyke
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

6.  Cooperativity of Rb, Brca1, and p53 in malignant breast cancer evolution.

Authors:  Prashant Kumar; Malini Mukherjee; Jacob P S Johnson; Milan Patel; Bing Huey; Donna G Albertson; Karl Simin
Journal:  PLoS Genet       Date:  2012-11-15       Impact factor: 5.917

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.